As I write this blog in early December the Dow is reaching 14 month highs, indicating a belief that the worst is behind us. While many believe there will be more bumps in the road and the unemployment picture hasn’t improved much, the tide is changing.
Here’s another example of life imitating art—SPELCO (Special Parachute Equipment and Logistics Consortium) is working on a personal glider that looks straight outta Science Fiction. With its glide ratio of 5:1 and self-propulsion system, the “Gryphon” could become an invaluable tool in the future warfighter’s arsenal.
Back at CES ’09, I had the chance to preview Hillcrest Labs’ MEMs Accelerometer-based motion-control technology. They’ve since marketed it as a consumer device, the Loop Pointer. Essentially an air mouse on steroids, the Loop Pointer is one of the coolest gadgets I’ve seen in a while.
40 years ago, Neil Armstrong emerged from the Lunar Module Eagle, and stepped into history. He became the first human being to step foot on the moon, forever changing the scientific and engineering communities. And yet, 40 years later, the space program is a shell of its former self. Public enthusiasm is at an all-time low. How did we get to this point?
Two advocacy groups asked U.S. antitrust regulators on Monday to block Google's purchase of AdMob, a provider of advertising services for mobile phones, on antitrust grounds and to address privacy issues raised by the deal.
From the German town that unwittingly advertised pornography on its website to the American who interrupted his wedding to update his Facebook and Twitter accounts, the world was full of weird stories in 2009.
The Internet made shopping without checkout lines a no-brainer. Now, some Web companies are betting that people are ready to forsake another shopping tradition: tangible products. Virtual goods, which exist as digital bits on computers and cellphones, have grown more popular in the past year as important accoutrements for increasingly Web-oriented lives.
Chinese archeologists have unearthed a large third-century tomb, which they say could be that of Cao Cao, the legendary politician and general famous throughout East Asia for his Machiavellian tactics. The tomb, discovered in Xigaoxue village near the ancient Chinese city of Anyang, Henan Province, has an epitaph and inscription that appear to refer to Cao Cao, Central China Television said on Sunday.
Vias don't go well in pads, of course. In fact, I think it's fair to say that vias go as well in pads as large igneous rocks go in peanut butter and jelly sandwiches. But it's not just vias in...
Grainy cell phone images are often used against cops accused of using excessive violence. Now, officers are being armed with their own cameras. The so-called head cameras are the latest technology to come from Taser International Inc., makers of the stun guns popular with law enforcement.
Baxter Completes Production of First Commercial Batches of A/H1N1 Pandemic Vaccine
Boston Scientific Corporation (NYSE: BSX) today announced the completion of a public offering of $2 billion aggregate principal amount of its senior notes under the Company's shelf registration statement. The public offering consists of $850 million of 4.50 percent notes due January 2015, $850 mill
Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Nelda Connors as a Director. Ms. Connors, 44, is President of the Electrical and Metal Products division of Tyco International. Previously, she served as Vice President at Eaton Corporat
Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By GuidantDecember 29, 2009 9:02 am | by Boston Scientific | News | Comments
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding the Department's investigation relating to certain post-market surveys conducted by Guidant Corporation before Boston Scientific acquired Guidant in 200
FDA has an impossible task, given the breadth of its scope and its limited resources. And given the accelerating emergence of promising new diagnostic and therapeutic capabilities, the challenge isn’t shrinking. For example, the stimulus legislation provides NIH with $10 billion for new...